What is Circulogene?
Circulogene operates as a Liquid Biopsy Center, dedicated to providing best-in-class molecular and genomic tests for comprehensive profiling of solid tumors across all disease stages. The company's innovative offerings include LungLifeAI for the assessment of indeterminate pulmonary nodules and OncoGenDx for critical precision oncology decisions. By leveraging advanced methodologies that combine next-generation sequencing and PCR technology, Circulogene enhances the detection and monitoring of cancer-associated genes. Their commitment to personalizing and optimizing treatment plans has already benefited over 25,000 cancer patients, with a clear focus on improving patient outcomes and survival rates through cutting-edge diagnostic solutions.
How much funding has Circulogene raised?
Circulogene has raised a total of $2.3M across 3 funding rounds:
Private Equity
$1.2M
Debt
$750K
Debt
$350K
Private Equity (2015): $1.2M, investors not publicly disclosed
Debt (2016): $750K, investors not publicly disclosed
Debt (2020): $350K supported by PPP
What's next for Circulogene?
The recent major strategic investment in Circulogene signals a robust phase of expansion and technological advancement. With a foundation built on supporting thousands of cancer patients through advanced genomic profiling, the company is well-positioned to scale its operations and further refine its diagnostic tools. This capital infusion is expected to accelerate the development and deployment of its innovative tests, potentially broadening its market reach in precision oncology and liquid biopsy. Circulogene's strategic focus on integrating next-generation sequencing and PCR technologies suggests a continued emphasis on enhancing diagnostic accuracy and patient-specific treatment strategies, aiming to solidify its leadership in the oncology diagnostics sector.
See full Circulogene company page
